Moberg Pharma AB (STO:MOB), a Swedish pharmaceutical company, announced on Monday that it has appointed Shaw Sorooshian as VP and chief medical officer of the company, effective autumn of 2018.

Most recently, Sorooshian was senior director, Global Medical Affairs at Sobi AB (Swedish Orphan Biovitrum). Prior to that, he held senior positions at Shire, Lundbeck and Organon Laboratories.

Sorooshian will be replacing Kjell Rensfeldt in the management team, who will be retiring during autumn 2018, but will continue to serve as senior advisor to Moberg Pharma on a part-time basis.

Moberg Pharma's portfolio includes the OTC brands Kerasal, Kerasal Nail, New Skin, Dermoplast and Domeboro.